

EXPERT MEETING ON
NON-METASTATIC NSCLC
OCTOBER 20-22, 2026 MADRID

SCIENTIFIC COMMITTEE:
SOLANGE PETERS, FEDERICO CAPPUZZO



SCIENTIFIC BOARD

Federico Cappuzzo Rome IT
Solange Peters Lausanne CH

STEERING COMMITTEE

Federico Cappuzzo Rome IT
Tina Cascone Houston TX, US
Rafał Dziadziuszko Gdansk PL
Corinne Faivre-Finn Manchester UK
Enriqueta Felip Barcelona ES
Patrick Forde Baltimore MD, US

Edward B. Garon Santa Monica CA, US
Oliver Gautschi Lucerne CH
Lizza Hendriks Maastricht NL
Hidehito Horinouchi Tokyo JP
Rina Hui Sydney AU
Cécile Le Pechoux Paris FR
Umberto Malapelle Naples IT
Solange Peters Lausanne CH
Ramón Rami-Porta Barcelona ES

Biagio Ricciuti Boston, MA, US
Fernando López Ríos Madrid, ES
Delvys Rodriguez-Abreu Gran Canaria ES
Julia Kathleen Rotow Boston MA, US
Edgardo Santos Miami, FL, US
Brendon M. Stiles New York NY, US
Paul Van Schil Antwerp BE

EXPERTS

Joachim Aerts Rotterdam NL
Charu Aggarwal Philadelphia PA, US
Myung-Ju Ahn Seoul KR
Maria E. Arcila New York NY, US
Andrea Ardizzoni Bologna IT
Oscar Arrieta Mexico City MX
Mark M. Awad Boston MA, US
Anne Marie Baird Dublin IE
Jair Bar Ramat Gan IL
Lyudmila A. Bazhenova San Diego CA, US
Giovanni Blandino Rome IT
Marianna Cerro Rome IT
Byoung Chul Cho Seoul KR
Alessio Cortellini Rome / London IT / UK
Alessandra Curioni Fontecedro Fribourg CH
Urania Dafni Athens GR
Marzia Del Re Rome IT
Vincenzo Pio Di Noia Rome IT
Anne-Marie Dingemans Rotterdam NL
Francesca Fusco Rome IT
Shirish M Gadgeel Detroit MI, US
Marina Chiara Garassino Chicago IL, US - Milan IT
Rosario García Campelo Coruña ES
Pilar Garrido López Madrid ES
Yasushi Goto Tokyo JP
Jhanelle Gray Tampa FL, US
Roy S. Herbst New Haven CT, US
Fred Hirsch New York NY, US
Pasi A. Janne Boston MA, US
Ola Khorshid Giza EG
Natasha Leighl Toronto CA
Molly Li Hong Kong HK
Jessica Lin Boston MA, US
Helena Linardou Athens GR

Mervat Mahrous Riyadh SA
Edoardo Mercadante Rome IT
May Lucie Meyer Lausanne CH
Tetsuya Mitsudomi Osaka JP
Nicola Normanno Rome IT
Silvia Novello Turin IT
Alina Catalina Palcau Rome IT
Giovanni Pappagallo Negrar di Valpolicella VR, IT
Claudia Parisi Paris FR
Luis Paz-Ares Rodríguez Madrid ES
Giuseppe Perrone Rome IT
Luis E Raez Hollywood FL, US
Sara Ramella Rome IT
Karen Reckamp Los Angeles CA, US
Noemi Reguart Aransay Barcelona ES
Christian Rolfo Columbus OH, US
Kurt Schalper New Haven CT, US
Suresh Senan Amsterdam NL
Takashi Seto Fukuoka JP
Ferdinando Skoulidis Houston TX, US
Egbert Frederik Smit Leiden NL
Marta Soares Porto PT
Ross Soo Singapore SG
Hector J. Soto Parra Catania IT
Rolf Stahel Zurich CH
Rocco Trisolini Rome IT
Giulia Veronesi Milan IT
Ignacio I. Wistuba Tampa FL, US
Jüergen Wolf Cologne DE
Yi-Long Wu Guangdong CN
Alona Zer Israel IL

EXPERT MEETING ON NON-METASTATIC NSCLC

OCTOBER 20-22, 2026 MADRID
ONLY YOU HOTEL ATOCHA

The management of non-metastatic non-small cell lung cancer (NSCLC) is rapidly evolving. The integration of immune checkpoint inhibitors (IO), targeted therapies (TKIs), and multimodal strategies into earlier stages of disease has significantly modified traditional treatment algorithms. Advances in molecular diagnostics, perioperative systemic therapy, and the emerging role of minimal residual disease (MRD) assessment are reshaping clinical decision-making across stages I-III. Despite these advances, several areas of uncertainty remain. Key open questions concern optimal staging and biomarker assessment, patient selection for perioperative IO or TKI therapy, the evolving definition of resectability—particularly in stage III N2 disease—and treatment sequencing in patients who relapse after receiving immunotherapy in curative-intent settings. In addition, the management of unresectable stage III disease continues to generate discussion regarding the most appropriate therapeutic strategies.

The Second Expert Meeting on Non-Metastatic NSCLC aims to provide a structured multidisciplinary forum to review current evidence, address areas of debate, and identify points of agreement through expert discussions.

The objectives of the meeting are:

- To clarify staging and diagnostic pathways, including the role of biomarkers and MRD.
- To discuss evidence-based management of resectable stage I-II and stage III disease.
- To examine therapeutic sequencing and resistance patterns following early-stage immunotherapy.
- To identify priorities for future clinical research.

Separately, on the last day, a consensus effort will be conducted, through an interactive driven approach. Through a meeting consensus manuscript, the community would aim at harmonizing clinical practice and define key areas for future development in non-metastatic NSCLC.

The participation to the consensus part is optional for all the industry partners and can be considered as a separated activity.

DAY 1 **OCTOBER 20, 2026 | 14.00 - 18.00 (4 HOURS)**
14.00–14.20 **Presentation of the event** (Steering Committee)

BIOMARKERS AND IMAGING
14.20–15.40 **Staging and diagnosis**
Chair Oliver Gautschi
14.20–14.45 **Basics on staging workup** Ramón Rami-Porta
14.45–15.10 **Standard molecular diagnosis and biomarkers** Fernando López Rios
15.10–15.40 **MRD, current knowledge** Umberto Malapelle

15.40–16.00 Coffee break

16.00–17.40 **RESECTABLE DISEASE STAGE I-II**
Chair Hidehito Horinouchi
16.00–16.30 **Surgical approach in stage I-II** Paul Van Schil
16.30–17.00 **Perioperative & (neo) adjuvant IO in early disease, a global overview**
Tina Cascone
17.00–17.40 **Role of perioperative TKIs** Julia Kathleen Rotow
17.40–18.00 **Wrap-up / closing remarks**

DAY 2 **OCTOBER 21, 2026 | 09.00-17.00 (8 HOURS)**
09.00–10.15 **FOCUS ON STAGE I/II N0 (8th TNM)**
Chair Piergiorgio Solli
09.00–09.40 **Radiation and IO in stage I/II N0** Corinne Faivre-Finn
09.40–10.15 **Perioperative IO or TKI in stage I/II** Patrick Forde

10.15–10.30 Coffee break

10.30–12.30 **FOCUS ON STAGE III N2 (8th TNM)**
Chair Delvys Rodriguez-Abreu
10.30–11.10 **Perioperative chemo and IO focusing on all stage III** Enriqueta Felip
11.10–11.50 **Perioperative chemo and TKI in stage IIIN2** Rina Hui
11.50–12.30 **Definition of resectability** Brendon M. Stiles

12.30–13.30 Lunch break

- 13.30-15.00

1st LINE METASTATIC DISEASE AFTER IO (EARLY STAGE)

Chair Lizza Hendriks

13.30-14.10

IO resistance and rechallenge

Edward B. Garon

14.10-15.00

Treatment options after early-stage IO

Biaggio Ricciuti
- 15.00-15.15

Coffee break
- 15.15-17.00

UNRESECTABLE STAGE III

Chair Edgardo Santos

15.15-16.00

Standards of care

Cecile le Pechoux

16.00-17.00

IO in unresectable stage III: promises and pitfalls

Rafal Dziadziuszko

DAY 3

OCTOBER 22, 2026 | 09.00-11.00 (2 HOURS)

09.00-11.00

CONSENSUS DISCUSSION SESSION - OPTIONAL FOR INDUSTRY

SEPARATED SESSION

Extended discussion, debate and voting

Questions (max 5 per topic; approx. 30 total)

INFO

VENUE

ONLY YOU HOTEL ATOCHA

P.º de la Infanta Isabel, 13, Retiro

28014 Madrid, ES

ORGANIZING SECRETARIAT



MI&T srl Centro Direzionale Bolomnia

Via Guelfa, 5 - 40138 Bologna - Italy

Phone +39 051 220427 - Mobile +39 335 5918811

info@mitcongressi.it - www.mitcongressi.it

UNRESTRICTED GRANT BY:

DIAMOND



SILVER

